Key result
Higher splenic T1 is linked to ~1% higher odds of myocardial fibrosis in portal hypertension.
Why the study?
The exact role of portal hypertension in cirrhotic cardiomyopathy remains unclear, and it is uncertain whether subclinical myocardial dysfunction, oedema, and fibrosis also occur in non-cirrhotic portal hypertension.
Does non-cirrhotic portal hypertension lead to subclinical myocardial dysfunction, oedema, and fibrosis on multiparametric cardiac MRI comparable to liver cirrhosis?
Observational (n=111)
Does non-cirrhotic portal hypertension lead to subclinical myocardial dysfunction, oedema, and fibrosis on multiparametric cardiac MRI comparable to liver cirrhosis?
Patients with non-cirrhotic portal hypertension exhibit MRI markers of myocardial fibrosis, oedema, and hyperdynamic circulation similar to compensated cirrhosis, supporting the concept of a specific portal hypertensive cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Myocardial fibrosis markers in non-cirrhotic portal hypertension merit clinical awareness; supports portal hypertensive cardiomyopathy but leaves open prognostic value.
AIMS: The exact role of portal hypertension in cirrhotic cardiomyopathy remains unclear, and it is uncertain whether cardiac abnormalities also occur in non-cirrhotic portal hypertension (NCPH). This magnetic resonance imaging (MRI) study aimed to evaluate the presence of subclinical myocardial dysfunction, oedema, and fibrosis in NCPH. METHODS AND RESULTS: In this prospective study (2018-2022), participants underwent multiparametric abdominal and cardiac MRI including assessment of cardiac function, myocardial oedema, late gadolinium enhancement (LGE), and abdominal and cardiac mapping [T1 and T2 relaxation times, extracellular volume fraction (ECV)]. A total of 111 participants were included [44 participants with NCPH (48 ± 15 years; 23 women), 47 cirrhotic controls, and 20 healthy controls]. The cirrhotic group was dichotomized (Child A vs. Child B/C). NCPH participants demonstrated a more hyperdynamic circulation compared with healthy controls (cardiac index: 3.7 ± 0.6 vs. 3.2 ± 0.8 L/min/m², P = 0.004; global longitudinal strain: -27.3 ± 4.6 vs. -24.6 ± 3.5%, P = 0.022). The extent of abnormalities indicating myocardial fibrosis and oedema in NCPH was comparable with Child A cirrhosis (e.g. LGE presence: 32 vs. 33 vs. 69%, P = 0.004; combined T1 and T2 elevations: 46 vs. 27 vs. 69%, P = 0.017; NCPH vs. Child A vs. Child B/C). Correlations between splenic T1 and myocardial T1 values were found (r = 0.41; P = 0.007). Splenic T1 values were associated with the presence of LGE (odds ratio, 1.010; 95% CI: 1.002, 1.019; P = 0.013). CONCLUSION: MRI parameters of myocardial fibrosis and oedema were altered in participants with NCPH to a similar extent as in compensated cirrhosis and were associated with splenic markers of portal hypertension, indicating specific portal hypertensive cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Isaak et al. (2022) conducted an observational in Non-cirrhotic portal hypertension (NCPH) and liver cirrhosis (n=111). Non-cirrhotic portal hypertension (NCPH) and splenic T1 mapping vs. Healthy controls (n=20) and cirrhotic controls (Child A and Child B/C, n=47) was evaluated on Association between splenic T1 values and presence of myocardial late gadolinium enhancement (LGE) (OR 1.010, 95% CI 1.002-1.019, p=0.013). Non-cirrhotic portal hypertension showed myocardial LGE and splenic T1 was associated with LGE presence.
Synapse has enriched 10 related papers. Consider them for comparative context: